Healthcare: These Two Stocks Are On Different Paths, But Both Remain Risky *** INDUSTRY FOCUS ***

TL;DR

Valeant Pharmaceuticals is struggling with controversies and leadership issues, while GW Pharmaceuticals has made a breakthrough in creating a drug derived from marijuana to treat childhood epilepsy.

Transcript

Michael Douglass: Healthcare: a study in contrasts. This is Industry Focus. Hi, Fools! Healthcare analyst Michael Douglass here today with regular Industry Focus contributor Todd Campbell. I'm filling in for Kristine Harjes because she is just getting back from vacation, and we've got a great show for you today. Todd, welcome back! Todd Campbell: I... Read More

Key Insights

• 🧑‍🏭 Leadership and company culture are important factors that can significantly impact a company's valuation, growth prospects, and M&A strategy.
• 🥺 Valeant Pharmaceuticals has faced controversies and leadership issues, leading to a decline in market cap and scrutiny from stakeholders.
• 😀 GW Pharmaceuticals has made a breakthrough in creating a marijuana-derived drug for childhood epilepsy, but faces challenges such as a small patient population and potential competition from dispensaries.

Questions & Answers

Q: What has led to the decline of Valeant Pharmaceuticals?

Valeant has faced scrutiny and controversies due to price hikes on drugs and questionable accounting practices, leading to a decline in its market cap and the departure of their CEO.

Q: What is the potential impact of GW Pharmaceuticals' breakthrough in creating a drug derived from marijuana?

If GW Pharmaceuticals receives FDA approval, their drug could be a major breakthrough for patients with childhood-onset epilepsy. However, the small patient population and potential competition from dispensaries could limit commercial success.

Q: What factors should investors consider when evaluating Valeant Pharmaceuticals?

Investors should evaluate both the gap and non-gap financial results of Valeant, as well as the company's ability to find new leadership and restore confidence in its future growth prospects.

Q: Is GW Pharmaceuticals a promising investment opportunity?

While GW Pharmaceuticals has achieved a significant breakthrough, the commercial potential of their drug may be limited. Investors should approach the company with caution and consider the uncertainties surrounding the marijuana market.

Summary & Key Takeaways

• Valeant Pharmaceuticals has faced numerous controversies, including price hikes on certain drugs and questionable accounting practices, leading to the departure of their CEO.

• GW Pharmaceuticals has achieved a breakthrough in creating a drug derived from marijuana to treat childhood epilepsy, with potential FDA approval in the near future.